REGENXBIO
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, REGENXBIO sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
REGENXBIO: 9 sponsored US clinical trials, 2 recruiting.
REGENXBIO sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 2 trials.
Top-decile sponsor footprint
REGENXBIO ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
NCT05683379
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
NCT07236606
CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
NCT03566043
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
NCT04571970
Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients
NCT04148001
Mucopolysaccharidosis Type II Natural History
NCT03529786
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
NCT03066258
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
NCT02651675
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the REGENXBIO pipeline
2 recruiting of 9 indexed (22% open); 4 completed (44%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Duchenne Muscular Dystrophy (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
REGENXBIO: open-pipeline peers nationwide
Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
REGENXBIO sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this REGENXBIO page
9 registered trials is a research-attention snapshot, not an endorsement of REGENXBIO or any single study.
- 2 of REGENXBIO's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Duchenne Muscular Dystrophy is the condition REGENXBIO studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
REGENXBIO pipeline card: 9 registered trials from official public datasets.Report a data error.